 The study plans to treat at least 60 pediatric subjects, male and female, between the ages of 2 months and 17 years inclusive with acute Graft versus Host Disease aGVHD following allogeneic hematopoietic stem cell transplant HSCT that has failed to respond to treatment with systemic corticosteroid therapy. Subjects may have Grades C and D aGVHD involving the skin, liver andor gastrointestinal GI tract or Grade B aGVHD involving the liver andor GI tract, with or without concomitant skin disease. 